- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00126386
Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community
November 18, 2011 updated by: Alberta Health services
Zoledronic Acid (Zometa) for the Management of Tumor-induced Hypercalcemia (TIH) and Malignant Bone Pain (MBP) in the Community: A Feasibility Study
Treatment in the home and hospice of long-term care facilities, particularly for non-ambulatory patients, could provide significant advantages for patients and for the region.
The Calgary Health Region has a unique resource in the home parenteral therapy program (HPTP).
With the assistance of HPTP, patients requiring bisphosphonate treatment for the management of tumor-induced hypercalcemia (TIH) or malignant bone pain (MBP) could be treated in the community (ie at home).
However, the resources required and the costs associated with community-based (homes, hospices, long-term care facilities) treatment of TIH and MBP need to be identified and evaluated so as to guide future regional decision making.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Treatment in the home and hospice of long-term care facilities, particularly for non-ambulatory patients, could provide significant advantages for patients and for the region.
The Calgary Health Region has a unique resource in the home parenteral therapy program (HPTP).
With the assistance of HPTP, patients requiring bisphosphonate treatment for the management of TIH or MBP could be treated in the community (ie at home).
However, the resources required and the costs associated with community-based (homes, hospices, long-term care facilities) treatment of TIH and MBP need to be identified and evaluated so as to guide future regional decision making.
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
If hypercalcemic:
- Serum corrected Ca+++>= 2.5 mmol/L and symptomatic hypercalcemia
- Asymptomatic hypercalcemia with corrected Ca+++>= 3.0 mmol/L
- Moderate to severe intolerable pain (>=6/10 on numerical rating scale [NRS]) despite optimal treatments with a strong opioid such as morphine, hydromorphone, fentanyl, oxycodone or methadone
- Radiotherapy bone pain related to metastatic bone disease
Exclusion Criteria:
- Not on a regular bisphosphonate regimen
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
feasibility of treating hypercalcemia in the community
|
resources required
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jose Pereira, MD, Alberta Cancerboard
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2004
Study Completion (ACTUAL)
September 1, 2006
Study Registration Dates
First Submitted
August 2, 2005
First Submitted That Met QC Criteria
August 2, 2005
First Posted (ESTIMATE)
August 4, 2005
Study Record Updates
Last Update Posted (ESTIMATE)
November 21, 2011
Last Update Submitted That Met QC Criteria
November 18, 2011
Last Verified
August 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17280
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on Zoledronic acid (Zometa)
-
Sun Yat-sen UniversityNovartisCompleted
-
Novartis PharmaceuticalsCompleted
-
Thomas LundCompleted
-
Massachusetts General HospitalDana-Farber Cancer Institute; Brigham and Women's Hospital; American Society...CompletedMultiple MyelomaUnited States
-
University of LouisvilleNovartis Pharmaceuticals; James Graham Brown Cancer CenterTerminatedCarcinoma, Non-Small Cell Lung | Metastases | Carcinoma, Small Cell LungUnited States
-
University of Alabama at BirminghamNovartis PharmaceuticalsCompleted
-
Peter Bushunow MDNovartis PharmaceuticalsTerminatedNon Small Cell Lung Cancer | Malignant Pleural EffusionUnited States
-
Fudan UniversityNovartisCompletedMetastatic Breast Cancer | Bone MetastasesChina
-
Tehran University of Medical SciencesNovartisUnknownBone Marrow Transplantation | Beta-ThalassemiaIran, Islamic Republic of
-
Novartis PharmaceuticalsCompleted